Advanced Accelerator Applications: Clinical Trials

13 trials sponsored by Advanced Accelerator Applications, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 4 terminated, 1 active not recruiting, 1 recruiting. 13 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 113Completed 6, Terminated 4, Active not recruiting 1, Recruiting 1, Withdrawn 1
Phase 27Completed 3, Terminated 3, Withdrawn 1

Follow Advanced Accelerator Applications: new trials by email

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate Cancer
[177Lu]Lu-PSMA-617, Ipilimumab - Very High Risk Prostate Carcinoma
Phase 1 / Phase 2TerminatedUniversity Hospital, Essen12025-08-252026-03-13
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Cabozantinib, Lu-177 - Neuroendocrine Tumors
Phase 1Active not recruitingProvidence Health & Services62022-12-282026-04-13
Lutathera and ASTX727 in Neuroendocrine Tumours
ASTX727, Lutathera - Neuroendocrine Tumors
Phase 1RecruitingImperial College London372022-04-252026-11-12
EBRT + Lu-PSMA for N1M0 Prostate Cancer
177Lu-PSMA-617, EBRT - Prostatic Neoplasm
Phase 1CompletedThe Netherlands Cancer Institute142021-12-202025-12-10
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents
177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma
Phase 1 / Phase 2WithdrawnSue O'Dorisio2020-08-042021-06-08
177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
177Lu-DOTA-TATE + olaparib - Clinical Trial, Phase I, Neuroendocrine Tumors
Phase 1CompletedVastra Gotaland Region182020-04-232026-04-14
[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake
[177Lu]-NeoB, [68Ga]-NeoB, LCZ696 - Neoplasms
Phase 1 / Phase 2CompletedAdvanced Accelerator Applications352019-07-242026-07-28
177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer
177Lu-PSMA-R2 - Prostatic Neoplasm
Phase 1TerminatedAdvanced Accelerator Applications272018-05-242025-05-13
68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
[68Ga]-PSMA-R2 - Prostate Cancer Metastatic
Phase 1 / Phase 2CompletedAdvanced Accelerator Applications302018-05-232020-11-17
Nivolumab and 177Lu-DOTA0-Tyr3-Octreotate for Patients With Extensive-Stage Small Cell Lung Cancer
Nivolumab, 177Lu-DOTA0-Tyr3-Octreotate - Small Cell Lung Cancer, Small Cell Lung Cancer Extensive Stage
Phase 1 / Phase 2CompletedGeorgetown University92017-11-202021-03-16
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
99mTc-Annexin V-128 SPECT - Endocarditis, Thrombosis
Phase 1 / Phase 2TerminatedInstitut National de la Santé Et de la Recherche Médicale, France112016-02-052021-08-26
99mTc-rhAnnexin V-128 a Phase I/IIa Study in Patients With Rheumatoid Arthritis (RA) or Ankylosing Spondylitis (AS)
99mTc-rhAnnexin V-128 - Rheumatoid Arthritis, Ankylosing Spondylitis
Phase 1 / Phase 2TerminatedAdvanced Accelerator Applications162014-12-112020-10-08
99mTc-rhAnnexin V-128: a First In Man Study in Healthy Volunteers
Kit for the Preparation of 99mTc-rhAnnexin V-128 - Healthy Adult Volunteers
Phase 1CompletedAdvanced Accelerator Applications142013-04-012019-11-21

Conditions studied

Neuroendocrine Tumors (4)  ·  Neoplasms (3)  ·  Prostatic Neoplasms (3)  ·  Genital Neoplasms, Male (2)  ·  Neoplasms by Site (2)  ·  Prostatic Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Arthritis, Rheumatoid (1)  ·  Endocarditis (1)  ·  Genital Diseases, Male (1)  ·  Mesothelioma (1)  ·  Paraganglioma (1)  ·  Pheochromocytoma (1)  ·  Small Cell Lung Carcinoma (1)  ·  Spondylitis, Ankylosing (1)

Interventions

lutetium Lu 177 dotatate (4)  ·  Ipilimumab (1)  ·  Lutetium-177 (1)  ·  Nivolumab (1)  ·  Pluvicto (1)  ·  Receptor Protein-Tyrosine Kinases (1)  ·  Valsartan (1)  ·  cabozantinib (1)  ·  decitabine and cedazuridine drug combination (1)  ·  olaparib (1)  ·  sacubitril (1)  ·  sacubitril and valsartan sodium hydrate drug combination (1)

Countries

United States (6)  ·  France (2)  ·  Netherlands (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  Austria (1)  ·  Canada (1)  ·  Germany (1)  ·  Sweden (1)  ·  Switzerland (1)

Top investigators

Chul Kim, MD (1)  ·  Dominique Le Guludec, MD, PhD (1)  ·  Hagen Kennecke, MD (1)  ·  John Prior, MD, PhD (1)  ·  M. Sue O'Dorisio, MD, PhD (1)  ·  Rohini Sharma, Professor (1)  ·  Terrence D. Rudy, MD, FRCPC (1)  ·  Wouter V Vogel, MD, PhD (1)

Results publications

PMID 32616557, PMID 33189510, PMID 34829796, PMID 36959540, PMID 37879695, PMID 38753757, PMID 39915126

NIH funding

2017 (1), 2019 (1), 2023 (1)